These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 19302249)

  • 1. Safety and tolerability of omalizumab.
    Corren J; Casale TB; Lanier B; Buhl R; Holgate S; Jimenez P
    Clin Exp Allergy; 2009 Jun; 39(6):788-97. PubMed ID: 19302249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omalizumab: anti-IgE monoclonal antibody E25, E25, humanised anti-IgE MAb, IGE 025, monoclonal antibody E25, Olizumab, Xolair, rhuMAb-E25.
    BioDrugs; 2002; 16(5):380-6. PubMed ID: 12408744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spotlight on omalizumab in allergic asthma.
    Bang LM; Plosker GL
    BioDrugs; 2004; 18(6):415-8. PubMed ID: 15571425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma.
    D'Amato G; Piccolo A; Salzillo A; Noschese P; D'Amato M; Liccardi G
    Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):225-31. PubMed ID: 19075985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of omalizumab in asthma.
    Tan RA; Corren J
    Expert Opin Drug Saf; 2011 May; 10(3):463-71. PubMed ID: 21401438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omalizumab: new drug. Asthma: too many unknowns for an anti-IgE.
    Prescrire Int; 2007 Oct; 16(91):179-82. PubMed ID: 17926440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
    Vignola AM; Humbert M; Bousquet J; Boulet LP; Hedgecock S; Blogg M; Fox H; Surrey K
    Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Churg-strauss syndrome in patients treated with omalizumab.
    Wechsler ME; Wong DA; Miller MK; Lawrence-Miyasaki L
    Chest; 2009 Aug; 136(2):507-518. PubMed ID: 19411292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.
    Holgate ST; Chuchalin AG; Hébert J; Lötvall J; Persson GB; Chung KF; Bousquet J; Kerstjens HA; Fox H; Thirlwell J; Cioppa GD;
    Clin Exp Allergy; 2004 Apr; 34(4):632-8. PubMed ID: 15080818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Omalizumab treatment in patients with asthma: summary of Meir Medical Center experience with 47 patients].
    Shitrit D; Talker O; Metabichek A; Yaakovi I
    Harefuah; 2012 Apr; 151(4):216-9, 254, 253. PubMed ID: 22616149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omalizumab for asthma in adults and children.
    Normansell R; Walker S; Milan SJ; Walters EH; Nair P
    Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD003559. PubMed ID: 24414989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of omalizumab in the treatment of severe allergic asthma.
    Chapman KR; Cartier A; Hébert J; McIvor RA; Schellenberg RR
    Can Respir J; 2006; 13 Suppl B(Suppl B):1B-9B. PubMed ID: 16909166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of omalizumab in pre-filled syringes in patients with allergic (IgE-mediated) asthma.
    Somerville L; Bardelas J; Viegas A; D'Andrea P; Blogg M; Peachey G
    Curr Med Res Opin; 2014 Jan; 30(1):59-66. PubMed ID: 24028677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omalizumab: a review of its use in patients with severe persistent allergic asthma.
    McKeage K
    Drugs; 2013 Jul; 73(11):1197-212. PubMed ID: 23812924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial.
    Hanania NA; Alpan O; Hamilos DL; Condemi JJ; Reyes-Rivera I; Zhu J; Rosen KE; Eisner MD; Wong DA; Busse W
    Ann Intern Med; 2011 May; 154(9):573-82. PubMed ID: 21536936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma.
    Berger W; Gupta N; McAlary M; Fowler-Taylor A
    Ann Allergy Asthma Immunol; 2003 Aug; 91(2):182-8. PubMed ID: 12952113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-IgE for chronic asthma in adults and children.
    Walker S; Monteil M; Phelan K; Lasserson TJ; Walters EH
    Cochrane Database Syst Rev; 2004; (3):CD003559. PubMed ID: 15266491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-IgE for chronic asthma.
    Walker S; Monteil M; Phelan K; Lasserson TJ; Walters EH
    Cochrane Database Syst Rev; 2003; (3):CD003559. PubMed ID: 12917972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omalizumab: an update on efficacy and safety in moderate-to-severe allergic asthma.
    Chipps BE; Figliomeni M; Spector S
    Allergy Asthma Proc; 2012; 33(5):377-85. PubMed ID: 23026179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.
    Ayres JG; Higgins B; Chilvers ER; Ayre G; Blogg M; Fox H
    Allergy; 2004 Jul; 59(7):701-8. PubMed ID: 15180756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.